First-Line HIV/AIDS Treatments: Research
- Overweight HIVers See Lower CD4 Gain While on HIV Meds, Study Suggests (November 19, 2009)
An Interview With Nancy Crum-Cianflone, M.D., M.P.H.
From The Body
- HIV Treatment Lagging Behind for Many Infected Youth (May 3, 2009)
Health care providers often decide not to start young HIVers on HIV treatment even though their CD4 count is below 350, a new U.S. study has found.
From Johns Hopkins University
- Starting HIV Therapy May Improve Some Markers of Heart Health, Small Study Finds (April 21, 2009)
These new findings won't necessarily clear up the still-obscure relationship between HIV, HIV meds and heart disease, but they do support the idea that starting HIV treatment may not automatically jack up your cardiovascular risk.
From aidsmap.com
- High Adherence May Become Less Essential the Longer a Patient Maintains Viral Suppression on HAART, Findings Suggest (February 11, 2009)
Maximum adherence should always remain a goal when taking HAART. However, patients with sustained viral suppression on HAART are highly likely to maintain that viral suppression even in the face of adherence rates much lower than 95 percent, reports David Bangsberg, M.D., M.P.H.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- During First 45 Days Post HAART Initiation Patients Hospitalized Most Often for Non-AIDS-Defining Infections (February 9, 2009)
An interview with Stephen Berry, M.D.
In 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- People Diagnosed With Extremely Low CD4 Counts Usually Respond Well to Treatment, Study Finds (November 20, 2008)
From aidsmap.com
- First-Line HIV Treatment Regimens Last Longer Than Ever, Study Shows (September 16, 2008)
From aidsmap.com
- Dietary Intervention When Starting HAART Prevents the Increase in Lipids Independently of Drug Regimen: A Randomized Trial (July 25, 2007)
From International AIDS Society
- New Developments in the Management of HIV Treatment-Naive Patients (February 28, 2007)
Includes an analysis of research examining once-daily regimens, the use of viral decay rate to assess treatment efficacy, and issues related to primary HIV drug resistance.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Emergence of Drug Resistance and First-Line Combination Therapy in the Swiss HIV Cohort Study (February 26, 2007)
To view original study poster, click here (PDF).
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Study: No Advantage to Adding Fourth Drug to AIDS Cocktail (August 15, 2006)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Five-Year Study Demonstrates Similar Outcomes for NNRTI-Based and PI-Based Regimens (August 15, 2006)
In The XVI International AIDS Conference
- HIV JournalView: Tenofovir + Emtricitabine + Efavirenz vs. Zidovudine/Lamivudine + Efavirenz (February/March 2006)
An important study by Joel Gallant et al demonstrates the advantage of tenofovir + FTC in first-line therapy.
From The Body PRO
- More Sensitive Drug-Resistance Tests Yield Higher Rates of Multidrug Resistance in Treatment-Naive Patients (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
- Quadruple-NRTI Regimen No More Desirable Than Triple-NRTI Regimen in Treatment-Naive Patients, Study Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Two NRTIs or Three? Makes No Difference When Taken With Efavirenz, ACTG 5095 Finds (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- Virologic Suppression Between Six and 18 Months on New Regimen Can Predict Long-Term Outcomes (December 16, 2005)
[Archived Article]
In addition, patients who previously had a treatment interruption appear less likely to succeed on their current regimen.
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
- HAART Slows HIV Progression by 86%, Study Says (July 29, 2005)
[Archived Article]
Findings based on more than 3,200 participants in the Swiss HIV Cohort Study.
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Head-to-Head Comparison of Three Backbone Regimens With Efavirenz (July 27, 2005)
[Archived Article]
Although this study finds no clear winner, the abacavir + ddI arm appears to fall a bit short.
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Nucleoside-Sparing Regimens: Promising, but Still Experimental (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Lopinavir/Ritonavir Plus Efavirenz -- Worthy or Wacky? (July/August 2005)
[Archived Article]
A French study examines an NRTI-sparing regimen containing two of the most powerful antiretrovirals.
From The Body PRO
- Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
[Archived Article]
In Expert Opinion on Investigational Drugs, from The Body PRO
- The Impact of Patient Knowledge on HAART Initiation (April 2005)
[Archived Article]
Many patients don't feel they're given enough information about HIV treatment.
From The Body PRO
- K65R Mutation Revealed in 4 Non-Responders to Abacavir + Lamivudine + Tenofovir Failed Regimen -- Significance Unclear (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Multi-National Trial Confirms Superiority of 3-Drug Regimen Containing Efavirenz for the Treatment Naive (February 25, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
[Archived Article]
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- EuroSIDA Study Confirms Ability of Most HAART Regimens to Decrease Rates of Illness and Death (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Meta-Analysis of Triple-Combination Therapy in Treatment-Naive Patients (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Mortality Unaffected by Initial HAART Regimen Choice (February 24, 2005)
[Archived Article]
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A5095 and the Triple-Nucleoside Saga (January 2005)
[Archived Article]
A second look at the study that -- at the time -- appeared to doom Trizivir; part of HIV JournalView's Top 10 Research Reports of 2004.
In AIDS Treatment News, from The Body PRO
- Warning on Two Specific 3-Drug Regimens: Viread + Videx + Either Sustiva or Viramune (November 23, 2004)
[Archived Article]
A brief comment on the recently issued warning that both regimens frequently fail.
In AIDS Treatment News, from AIDS Treatment News
- CD4 Counts Rise More Slowly in Former Injection-Drug Users on HAART (November 11, 2004)
[Archived Article]
The long-term immune system damage caused by drugs like cocaine and heroin is cited as a cause.
From aidsmap.com
- Low CD4 Count Not an Obstacle to Successful HAART -- But Detectable Viral Load Is (November 8, 2004)
[Archived Article]
Even those with a CD4 count as low as 50 can dramatically reduce their long-term risk of disease progression if they start HAART -- provided they keep their viral load undetectable.
From aidsmap.com
- White Doctors Delay HIV Treatment for Their Black Patients, Study Says (November 3, 2004)
[Archived Article]
From HealthDayNews
- New Fixed-Dose Once-a-Day Starting Regimens: Interview With Cal Cohen, M.D. (October 26, 2004)
[Archived Article]
A leading AIDS physician looks at the advantages and disadvantages of Epzicom and Truvada for those who are first starting antiretroviral treatment.
In AIDS Treatment News, from AIDS Treatment News
- CD4 Gain Lower Among Older People Starting HAART Than Younger People (October 8, 2004)
[Archived Article]
Those over 50 were also much more likely to progress to AIDS after starting HAART, although paradoxically they were also more likely to reach an undetectable viral load.
From aidsmap.com
- Viral Load Test One Month After Starting HAART May Help Predict Treatment Success (September 3, 2004)
[Archived Article]
From aidsmap.com
- Four-Week Viral Load Results May Predict Virologic Outcome on HAART (September 1, 2004)
[Archived Article]
Abstract of a 24-week, 656-patient study in treatment-naive patients.
In Journal of Acquired Immune Deficiency Syndromes
- Boosted Fosamprenavir Works Well as First-Line Therapy (July 23, 2004)
[Archived Article]
A HAART regimen containing fosamprenavir and ritonavir is highly effective and well-tolerated when used as first-line therapy in patients with advanced HIV, according to the final published results from this major study.
In AIDS
- Zidovudine/Lamivudine/Abacavir May Be Effective Alone for Induction Maintenance (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- A Head-to-Head Comparison of Initial HIV Treatment With PI-, NNRTI- or NRTI-Based Regimens (July 14, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Data on HIV Disease Prognosis 5 Years After Initiating HAART (July 13, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- Patients Beginning HAART With a Low CD4+ Cell Count Respond Well (July 12, 2004)
[Archived Article]
A study examining the characteristics of "late presenters" -- those whose HIV disease has already progressed by the time they're diagnosed.
In The XV International AIDS Conference, from The Body PRO
- Drug Resistance in Treatment-Naive Patients Only Briefly Impacts CD4 Counts (June 22, 2004)
[Archived Article]
From aidsmap.com
- Triple-Nucleoside Regimens Versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection (April 29, 2004)
[Archived Article]
Abstract of results from ACTG 5095, finding Trizivir (AZT/3TC/abacavir) to be far less effective at suppressing viral load than regimens consisting of efavirenz (Sustiva) plus two or three NRTIs.
In New England Journal of Medicine
- CROI 2004 Recap: Rout of the Minimalists (April 2004)
[Archived Article]
Summaries of research on once-daily therapy.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gender, Youth, Race/Ethnicity, Treatment Interruption Tied to Risk for Virologic Failure (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
[Archived Article]
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Clinical Efficacy of Antiretroviral Combination Therapy Based on Protease Inhibitors or Non-Nucleoside Analogue Reverse Transcriptase Inhibitors: Indirect Comparison of Controlled Trials (January 31, 2004)
[Archived Article]
Three-drug regimens containing a protease inhibitor are found to more effectively suppress HIV than three-drug regimens containing NNRTIs.
In British Medical Journal
- Emtricitabine: A New Nucleoside Analogue for Once-Daily Antiretroviral Therapy (January 2004)
[Archived Article]
In Expert Opinion on Investigational Drugs
- Combination, Order of Anti-HIV Drugs Make a Difference in First-Time Recipients (December 11, 2003)
[Archived Article]
A study finds that AZT + 3TC + efavirenz retains effectiveness longer than other first-line regimens.
From U.S. National Institute of Allergy and Infectious Diseases
- Interruption of Treatment Is Safe for Those Who Started Too Early (December 2003/January 2004)
[Archived Article]
A recent European study bolsters the idea that HIV-positive people who started treatment with CD4 counts over 350 can safely stop.
From HIV i-Base
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- FTC Compares Well to 3TC in Triple-NRTI Regimens (September 15, 2003)
[Archived Article]
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Better Suppression, Adherence With Once-Daily FTC/ddI/Efavirenz Than Most PI-Based Regimens (July 14, 2003)
[Archived Article]
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- HIV-Positive IV Drug Users Have Poorer Response to HAART (April 15, 2003)
[Archived Article]
From aidsmap.com
- Abacavir Arm Stopped in Clinical Trial (April 4, 2003)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Low-Level Viremia: Smoke or Fire? (April 2003)
[Archived Article]
A summary of study results from CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Who Won 2NN? You (April 2003)
[Archived Article]
A summary of the 2NN study presented at CROI 2003.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Retroviruses Conference Clinical News: Interview With Cal Cohen, M.D. (March 14, 2003)
[Archived Article]
Dr. Cohen discusses starting antiretroviral therapy (tenofovir vs. d4T, efavirenz vs. nevirapine), new protease inhibitor information (atazanavir and fos-amprenavir, a.k.a. "908") and antiretroviral-associated cardiovascular problems (the D:A:D study).
In AIDS Treatment News, from AIDS Treatment News
- AIDS Drug in Halted Trial Is Less Effective Taken Alone (March 13, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
[Archived Article]
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here
From U.S. National Institute of Allergy and Infectious Diseases
- Dear Healthcare Provider Letter From the Division of AIDS -- Concern About Trizivir Potency (Spring 2003)
[Archived Article]
Recap from Jeffrey T. Schouten, M.D., one of the A5095 study's investigators.
In STEP Perspective, from Seattle Treatment Education Project
- Key Therapeutic Decisions in Managing HIV Infection (Spring 2003)
[Archived Article]
An update on when to start, when to switch and when to stop, from STEP's conference review of Retrovirus 2003.
In STEP Perspective, from Seattle Treatment Education Project
- The 2NN Study (Spring 2003)
[Archived Article]
A summary of study results by Lara Strick, M.D.
In STEP Perspective, from Seattle Treatment Education Project
- More Regarding Tenofovir Versus d4T in Treatment-Naive Subjects (February 14, 2003)
[Archived Article]
Newly released data on bone-related side effects for some tenofovir users.
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Results of the 2NN Study: A Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The NEAT Study: GW433908 Efficacy and Safety in ART-Naive Subjects: Final 48-Week Analysis (February 14, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Lipid Changes in a Randomized Comparative Trial of First-Line Antiretroviral Therapy With Regimens Containing Either Nevirapine Alone, Efavirenz Alone or Both Drugs Combined, Together With Stavudine and Lamivudine (2NN Study) (February 13, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (February 12, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparative Incidence and Temporal Accumulation of PI and NRTI Resistance in HIV-Infected Subjects Receiving Lopinavir/Ritonavir or Nelfinavir as Initial Therapy (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efficacy and Safety of Tenofovir DF Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Preliminary Interim Results (February 11, 2003)
[Archived Article]
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- New Drug Holds Promise of Once-Daily Therapy (December 20, 2002)
[Archived Article]
From Canadian AIDS Treatment Information Exchange
- Research From the 42nd ICAAC: Starting Therapy (December 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Cost-Effectiveness Implications of the Timing of Antiretroviral Therapy in HIV-Infected Adults (November 25, 2002)
[Archived Article]
A study asserts that, generally speaking, the risks of lipodystrophy and heart disease are outweighed by the benefits of early HIV treatment.
In Archives of Internal Medicine
- Comparison of the Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy After 48 Weeks of Treatment (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Efficacy and Safety of GW433908/Ritonavir Once Daily in Therapy-Naive Subjects, 48-Week Results -- The SOLO Study (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Genotypic and Phenotypic Characterization of Virologic Failure Through 48 Weeks Among Treatment-Naive Patients Taking Tenofovir DF or Stavudine in Combination With Lamivudine and Efavirenz (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Immune Reconstitution Is Similar in Antiretroviral-Naive Subjects Following 1 Year of Therapy With a Triple NRTI-Based or Protease Inhibitor-Containing ARV Regimen (November 21, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- 104 Weeks Outcome of Simplified Regimens in PI-Experienced Patients (November 19, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Antiretroviral Treatment Regimens Suitable for Resource-Poor Settings (November 18, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- What to Start With and What to Include? Should Compounds With Non Cross-Resistance Profiles Be Preferentially Used in Initial or Late Therapy? (November 18, 2002)
[Archived Article]
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO
- Potential Impact of Once-Daily Regimens on Adherence to HAART (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Successful Switch From Stavudine to Once-Daily Tenofovir Based Regimen in Patients With Fully Suppressed HIV (October 26, 2002)
[Archived Article]
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Once-a-Day, Quadruple-Drug Therapy Found Highly Effective as Naive Treatment (October 14, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Data From the 14th International AIDS Conference: Spare the PIs (October 2002)
[Archived Article]
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
[Archived Article]
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- FTC Superiority Over d4T in Phase III Trial (September/October 2002)
[Archived Article]
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- New Treatment Guidelines (September/October 2002)
[Archived Article]
Review and analysis of the International AIDS Society-USA's new initial-treatment recommendation.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- ACTG 384 at Barcelona: The Bottom Line (August 9, 2002)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Antiretroviral Strategies in Naive HIV-Positive Subjects (ACTG 384) (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Evaluation of Immune Restoration Parameters in Antiretroviral Therapy-Naive Patients: Role of the Thymus in Naive T Cell Rise (COLA3003 Study) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Is Simplification to Triple Antiretroviral Therapy After Viral Suppression With Quadruple Therapy Initiated at the Time of Primary Infection Associated With Increased Low-Level Viral Breakthrough? (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Pharmacodynamic Effects of Zidovudine 600 mg Once Daily Versus Zidovudine 300 mg Twice Daily in Therapy-Naive HIV-Infected Patients (COD20002) (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Relationship of Immunological Markers and Thymic Index to CD4+ T Cells and HIV RNA at Baseline in Treatment Naive HIV-Infected Patients (July 11, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Abacavir/Lamivudine in Combination With Efavirenz, Amprenavir/Ritonavir or Stavudine: ESS40001 (CLASS) Preliminary 48-Week Results (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Efficacy of Tenofovir DF Monotherapy in Chronically HIV-1 Infected Antiretroviral Treatment-Naive Patients (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- In Routine Practice, the Durability of First-Line HAART Is Better for NNRTI Than PI-Based Regimens, Regardless of Baseline HIV Status (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Low Incidence of Grade III/IV Hepatotoxicity in First HAART: Observations From 1,100 Patients Followed for 1 Year (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Potency and Tolerability of Once-a-Day, Directly Observed Therapy for Inner-City, Minority Patients (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Resistance Profiles at Baseline and Following Virologic Failure for Subjects Randomized to Receive Abacavir/Efavirenz/Didanosine +/-; Hydroxyurea After Failing Initial NRTI +/- PI Therapy (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- When to Start HAART: Evidence to Support Initiating Therapy at CD4+ Lymphocyte Counts <350 Cells/mm3 (July 9, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Hydroxychloroquine, Hydroxycarbamide, and Didanosine as Economic Treatment for HIV-1 (May 23, 2002)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- More Once-Daily Antiretroviral Options (April 29, 2002)
[Archived Article]
Study results presented at Retrovirus 2002.
To read PDF, click here
In STEP Ezine, from Seattle Treatment Education Project
- Initial Antiretroviral Regimens (March 30, 2002)
[Archived Article]
In British Medical Journal
- Systematic Review and Meta-Analysis of Evidence for Increasing Numbers of Drugs in Antiretroviral Combination Therapy (March 30, 2002)
[Archived Article]
In British Medical Journal
- CHARM: A Phase III Open-Label, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of Adding Nevirapine and/or Hydroxyurea to a Triple Nucleoside-Based Antiretroviral Drug Regimen in Treatment-Naïve HIV-1-Infected Subjects (February 27, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- A Randomized Trial Comparing Two Four-Drug Antiretroviral Regimens With a Three-Drug Regimen in Advanced HIV Disease (Abstract 41) (February 26, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Determining the Relative Efficacy of Tenofovir DF Using Frequent Measurements of HIV-1 RNA During a Short Course of Monotherapy in Antiretroviral Drug Naive Individuals (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Clinical and Immunological Outcomes in Severely Immunosuppressed Naive Patients on Effective Protease Inhibitor-Based HAART (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Diverse Effects of NRTI-Associated Mutations on Resistance to Abacavir, Stavudine and Zidovudine in the ZORRO Trial (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Long-Term Outcome of Naive HIV-Infected Patients with Small Increases in CD4+ Cells After Successful Virological Suppression: A Study of Discordant Responses with HAART (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Prognosis of HIV-1 Infected Drug-Naive Patients Starting Potent Antiretroviral Therapy: Multi-Cohort Analysis of 12,040 Patients (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Virologic Response to Antiretroviral Therapy in Chronically HIV-1-Infected, Antiretroviral-Naive Adults with Baseline Genotypic Resistance (December 18, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- TMC125 Is a Highly Potent Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) in Antiretroviral Therapy (ART)-Naive, HIV-1 Infected Subjects (December 17, 2001)
[Archived Article]
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine and Efavirenz in Treatment-Naive HIV-Infected Adults: 24-Month Follow-Up of the ANRS 091 Trial (October 30, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Long-Term Follow-Up of Antiretroviral-Naive HIV-Infected Patients Treated with d4T and ddI (QD) and Nevirapine (BID or QD) in the VIRGO Study (October 29, 2001)
[Archived Article]
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Final Results of a Pilot, 48-Week Study of Amprenavir/Abacavir/Lamivudine (APV/ABC/3TC) in ART-Naive Subjects with HIV-1 Infection (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Greater Suppression of CD8 Activation with Four vs. Three Drugs in Early Stages of Primary HIV Infection (PHI) Despite Similar Plasma Virological Decay Rates (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir, Lamivudine and Amprenavir +/- Ritonavir Is a Potent and Well-Tolerated HAART Regimen in Therapy-Naive Subjects (Preliminary Results from GW Protocols) (COL30325) (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Monitoring Intracellular HIV-1 Replication in Blood and Lymphoid Tissue in Antiretroviral Naive Subjects Receiving Amprenavir (APV), Abacavir (ABC), and 3TC (COLA3003 Study) (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The PI-Sparing Compact Quad Regimen of Combivir (COM)/Abacavir (ABC)/Efavirenz (EFV) Is Potent and Well-Tolerated in Antiretroviral Therapy (ART) Naive Subjects With High Viral Loads: 24-Wk Data (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults (March 7, 2001)
[Archived Article]
In Journal of the American Medical Association
- The Effect of Hydroxyurea on Intracellular Deoxy- and Dideoxynucleoside Triphosphate Ratios in Naive Subjects Receiving ZDV, ABC, 3TC+- NVP over 48 Weeks -- CHARM Phosphorylation Substudy (February 7, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Low Two-Year Risk of Virologic Failure with First Regimen HAART (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-a-Day Treatment for HIV Infection: Final 48-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Once-Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Treatment-Naive HIV-Infected Adults: 64-Week Follow-Up of the ANRS 091 Trial (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Use of Trizivir to Simplify Therapy in HAART-Experienced Patients With Long-Term Suppression of HIV-RNA: TRIZAL Study (AZL30002) -- 24-Week Results (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Severe Liver Toxicity in Patients Receiving Two Nucleoside Analogues and a Non-Nucleoside Reverse Transcriptase Inhibitor (February 5, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- NZT4002: 64-week Analysis of Combivir (COM)-Based Triple and Quadruple Therapy in Antiretroviral-Naive, HIV-1-Infected Subjects (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- Studies Suggest AZT/3TC/Abacavir May Offer Adequate Potency (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- The Effects of Hydroxyurea or Placebo Combined with Efavirenz, Didanosine, and Stavudine in Treatment of Naive and Experienced Patients: Preliminary 24-Week Results From the Third Study (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- It Takes Two, Maybe (Spring 2000)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Selected Highlights from the 7th CROI: Combination Drug Studies (Spring 2000)
[Archived Article]
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
- Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy (January 12, 2000)
[Archived Article]
In Journal of the American Medical Association
- Choosing the Right Initial Antiretroviral Regimens (February 1999)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- d4T, ddI and nevirapine (NVP) in antiretroviral-naive patients: a convenient triple regimen (September 26, 1998)
[Archived Article]
In The 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Efficacy of the Combination of Stavudine (d4T), Didanosine (ddI), and Nevirapine (NVP) as Initial Antiretroviral Therapy and Following Treatment with HIV-1 Protease Inhibitors (June 30, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- How to Start Antiretroviral Therapy (June 29 and 30, 1998)
[Archived Article]
Summaries of studies on initial combinations.
In The 12th International AIDS Conference, from The Body PRO
- Combination Abacavir (1592, ABC)/Amprenavir (141W94) Therapy in HIV-1 Infected Antiretroviral Na´ve Subjects with CD4+ Cell Counts >400 cells/mL and Viral Load >5000 copies/mL (June 29, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- Indinavir in Combination with Zidovudine (ZDV) and Lamuvidine (3TC) in Treatment-Na´ve Patients with >500 CD4 Cells/mm3 (June 29, 1998)
[Archived Article]
In The 12th International AIDS Conference, from The Body PRO
- A Randomized Double-Blind Study of d4T + ddI versus ZDV + ddI as Initial Treatment in Subjects with CD4 Count <= 500 cells/mm3 (February 4, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
[Archived Article]
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Rationale for Combination Therapy (December 1996)
[Archived Article]
In HIV Newsline, from San Francisco General Hospital
- Nipping HIV in the Bud (August 1996)
[Archived Article]
In GMHC Treatment Issues, from Gay Men's Health Crisis
- New Double Vs. Triple Antiviral Combination Study, CD4 200-500, No Prior Treatment (December 1, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
- Hydroxyurea and ddI: French Study Published (September 1, 1995)
[Archived Article]
In AIDS Treatment News, from AIDS Treatment News
|
|
Advertisement
|
E-Mail
Glossary
Share
